par Dunger, David B;Bruggraber, SFA;Mander, AP;Marcovecchio, ML;Tree, T;Chmura, PJ;Knip, M;Schulte, AM;Mathieu, C;Cnop, Miriam ;And other members of, INNODIA consortium
Référence Trials, 23, 1, page (414)
Publication Publié, 2022-05-01
Référence Trials, 23, 1, page (414)
Publication Publié, 2022-05-01
Article révisé par les pairs
Titre: |
|
Auteur: | Dunger, David B; Bruggraber, SFA; Mander, AP; Marcovecchio, ML; Tree, T; Chmura, PJ; Knip, M; Schulte, AM; Mathieu, C; Cnop, Miriam; And other members of, INNODIA consortium |
Informations sur la publication: | Trials, 23, 1, page (414) |
Statut de publication: | Publié, 2022-05-01 |
Sujet CREF: | Sciences bio-médicales et agricoles |
Mots-clés: | Beta-cell function |
C-peptide | |
Master protocol | |
Phase 2 | |
Prevention | |
Trials | |
Type 1 diabetes | |
MeSH keywords: | Adolescent |
Adult | |
Biomarkers | |
COVID-19 | |
Child | |
Diabetes Mellitus, Type 1 -- diagnosis -- drug therapy | |
Humans | |
SARS-CoV-2 | |
Treatment Outcome | |
Langue: | Anglais |
Identificateurs: | urn:issn:1745-6215 |
info:doi/10.1186/s13063-022-06259-z | |
info:pii/10.1186/s13063-022-06259-z | |
info:pmid/35585600 | |
PMC9116021 |